Overview

Trial of Endostar Combined With CHOPT for T Cell Lymphoma

Status:
Unknown status
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of Endostar combined with CHOPT in the treatment of T cell lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Collaborator:
Simcere Pharmaceutical Co., Ltd
Treatments:
Endostar protein
Endostatins